MedPath

Evaluation of the effect of Interferon Alfa-2b in diabetic macular edema

Phase 2
Recruiting
Conditions
Diabetic macular edema.
unspecified diabetic retinopathy with macular edema
E11. 311
Registration Number
IRCT20230103057035N1
Lead Sponsor
Shahid Beheshti University of Medical Sciences
Brief Summary

Not available

Detailed Description

Not available

Recruitment & Eligibility

Status
Recruiting
Sex
All
Target Recruitment
49
Inclusion Criteria

Diabetic patients over 18 years old
Macular edema involving the center.
BCVA between 20/400-40/20
Central macular thickness greater than or equal to 300 µm
Requires 3 IVB injections in the next 12 weeks
Retinal clarity, pupillary dilation for OCT, and necessary cooperation for proper fundus photography

Exclusion Criteria

Not provided

Study & Design

Study Type
interventional
Study Design
Not specified
Primary Outcome Measures
NameTimeMethod
Decrease thickness of the central part of the macula. Timepoint: At the beginning of the study and one month after the third injection of bevacizumab. Method of measurement: Oct device (Optical coherence tomography).
Secondary Outcome Measures
NameTimeMethod
Improve visual acuity. Timepoint: Before the study and one month after the third injection of bevacizumab. Method of measurement: Optometry.
© Copyright 2025. All Rights Reserved by MedPath